One of the mechanisms of SPP1 in tumor promotion was to inhibit T cell activation, which can be used as an immune checkpoint and may compensate for the role of PD-L1 in inhibiting the function of cytotoxic T lymphocytes in CRC. The gene discussed is SPP1; the disease is colorectal carcinoma.